



July 3, 2012

John H. Johnson Assumes Role of Chairman

SEATTLE--(BUSINESS WIRE)-- **July 3, 2012**—Dendreon Corporation (NASDAQ: DNDN) today announced that John H. Johnson, president and chief executive officer, has assumed the additional title of Chairman of the Board, as of July 1, 2012. Mr. Johnson succeeds Dr. Mitchell H. Gold as Chairman. Dr. Gold will continue to serve as a director. These changes are part of a succession plan previously announced on February 1, 2012.

Douglas G. Watson, Lead Independent Director of the Company's Board, said, "John has proven to be an outstanding leader, and is making important progress in positioning Dendreon for long-term success. As Chairman, he will set the vision for Dendreon as we work to provide PROVENGE[®] to patients around the world."

Mr. Johnson commented, "This is an exciting time in the prostate cancer space, and Dendreon has a unique position in the marketplace with an entirely new treatment paradigm. I look forward to working with the Board and Dendreon management team as we work to improve our top and bottom line performance, creating value for shareholders and patients alike."

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE[®] (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington, and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit <http://www.dendreon.com/>.

This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects and potential revenue and earnings from product sales, and progress generally on commercialization efforts for PROVENGE. Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

Dendreon Corporation
Investor Relations
Nicole Soley, 206-455-2220
InvestorRelations@dendreon.com
or
Media Relations
April Falcone, 206-829-1622
media@dendreon.com

Source: Dendreon Corporation

News Provided by Acquire Media